Nanoparticles for Thrombolytic Therapy in Ischemic Stroke: A Systematic Review and Meta-Analysis of Preclinical Studies

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(2), P. 208 - 208

Published: Feb. 6, 2025

Background: Recombinant tissue plasminogen activator (rtPA) remains the standard thrombolytic treatment for ischemic stroke. Different types of nanoparticles have emerged as promising tools to improve benefits and decrease drawbacks this therapy. Among them, cell membrane-derived (CMD) nanomedicines gained special interest due their capability increase half-life particles in blood, biocompatibility, thrombus targeting. In order update evaluate efficacy these nanosystems, we performed a meta-analysis selected vivo preclinical studies. Methods: Preclinical studies stroke models been identified through search Pubmed database. We included rtPA-nanoparticles, which assessed infarct volume and/or neurological improvement. Nanosystems were compared with free (non-encapsulated) rtPA treatment. Standardized mean differences computed pooled estimate effect sizes lesion volumes scores. Subgroup analyses by risk bias, type nanoparticle, time administration also performed. Results: A total 18 publications meta-analysis. This was based on defined inclusion criteria. Our analysis revealed that rtPA-nanoparticles improved both scores Moreover, CMD showed better evolution other nanoparticles. Funnel plots exhibited asymmetry publication bias. Heterogeneity generally high, funnel plot Egger test some evidence bias did not achieve statistical significance trim-and-fill analysis. Conclusions: rtPA-encapsulating nanosystems shown scales treatment, had greatest beneficial effect.

Language: Английский

Serum Proteomic Markers in Patients with Systemic Sclerosis in Relation to Silica Exposure

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(6), P. 2019 - 2019

Published: March 16, 2025

Background: Systemic sclerosis (SSc) is a multisystem autoimmune disease characterised by fibrosis, vasculopathy, and immune dysfunction. Silica exposure has been associated with more aggressive phenotype of the disease, including diffuse cutaneous involvement interstitial lung disease. This study aims to identify proteomic differences between SSc patients exposed silica those not silica. Methods: An observational 32 (11 silica-exposed 21 non-exposed) was performed, occupational history quantitative analysis using SWATH-MS mass spectrometry. Differentially expressed proteins were analysed, functional pathway enrichment performed. Results: Eight showed significant groups, all reduced levels in patients: adiponectin, immunoglobulins (IGLV3-19, IGLV2-18), complement C2, alpha-2-macroglobulin, vitronectin, cytoplasmic actin 2, pigment epithelium-derived factor. Alterations pathways related fibrinolysis, activation, inflammation highlighted, suggesting that may influence pathogenesis worsen its clinical course. Conclusions: supports hypothesis only triggering factor for SSc, but also modulating progression through inflammatory, procoagulant, fibrotic pathways. The identification biomarkers could contribute phenotypic classification development personalised therapies. Future studies should expand cohort further investigate mechanisms these SSc.

Language: Английский